- published: 03 Feb 2012
- views: 2245
Create your page here
Sunday, 13 November 2016
-
remove the playlistOrphan Drug
-
remove the playlistLatest Videos
-
remove the playlistLongest Videos
- remove the playlistOrphan Drug
- remove the playlistLatest Videos
- remove the playlistLongest Videos
back to playlist
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk.
In just 12 hours you will:
- Gain a comprehensive overview of the orphan drugs industry and market
- Look at worldwide orphan drugs legislation
- Discover market access procedures for orphan drugs
- Understand some of the challenges that patients with rare diseases have to face
- Learn about the role of advocacy groups and rare disease networks
- Find out how rare disease research is funded in Europe and the US
- Discuss the importance of the value proposition
For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Orphan-Drugs
- published: 28 Jan 2013
- views: 559
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk.
In just 12 hours you will:
- Gain a comprehensive overview of the orphan drugs industry and market
- Look at worldwide orphan drugs legislation
- Discover market access procedures for orphan drugs
- Understand some of the challenges that patients with rare diseases have to face
- Learn about the role of advocacy groups and rare disease networks
- Find out how rare disease research is funded in Europe and the US
- Discuss the importance of the value proposition
For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Orphan-Drugs
- published: 28 Jan 2013
- views: 200
Chris Garabedian, Chief Executive Officer of Sarepta Therapeutics, presented at World Orphan Drug Congress USA 2013 on the topic, 'Leveraging a personalized medicine platform: an approach to treat all patient genetic sub-groups in a rare disease.'
• Establishing a foundation of evidence
• Standardizing the preclinical and clinical approach
• The regulatory environment
World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development.
For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
- published: 13 May 2013
- views: 1113
In this exclusive interview with Rare Disease Report, Ms Divino discusses the study’s methods, results, and conclusions. For complete details of the study, click here. https://ash.confex.com/ash/2014/webprogram/Paper68994.html
Reference
Divino V, Dekoven M, Wang W, et al. Budget impact of orphan drugs in U.S.: A 2007-2013 MIDAS data sales analysis. Presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco. Abstract #736.
- published: 10 Dec 2014
- views: 186
A presentation for BTEC 2320, describing the events before and the circumstances surrounding the Orphan Drug Act of 1983, and the Rare Disease Industry.
- published: 16 Nov 2011
- views: 200
Speaker: James H. Reese (FDA)
First plenary session: orphan designation around the World
Worldwide Orphan Medicinal Designation Workshop
10 March 2014
- published: 03 Apr 2014
- views: 439
Orphan drug
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.
In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.
According to Thomson Reuters in their 2012 publication "The Economic Power of Orphan Drugs", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act of 1983 (ODA) and similar Acts in other regions of the world and also driven by "high-profile philanthropic funding." The period between 2001 to 2011 was the "most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals." For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an "impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs." By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs.
This page contains text from Wikipedia, the Free Encyclopedia -
https://wn.com/Orphan_drug
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
21:45Orphan Drugs -- small market/big opportunity / Craig Kephart, President , Centric Health Resources
Orphan Drugs -- small market/big opportunity / Craig Kephart, President , Centric Health Resources -
2:10How to bring an orphan drug to market - why is there legislation for rare diseases?
How to bring an orphan drug to market - why is there legislation for rare diseases?How to bring an orphan drug to market - why is there legislation for rare diseases?
12 Hour MBA in Orphan Drugs The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk. In just 12 hours you will: - Gain a comprehensive overview of the orphan drugs industry and market - Look at worldwide orphan drugs legislation - Discover market access procedures for orphan drugs - Understand some of the challenges that patients with rare diseases have to face - Learn about the role of advocacy groups and rare disease networks - Find out how rare disease research is funded in Europe and the US - Discuss the importance of the value proposition For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Orphan-Drugs -
48:54Taking Advantage of the Orphan Drug Act - Webinar
Taking Advantage of the Orphan Drug Act - WebinarTaking Advantage of the Orphan Drug Act - Webinar
-
2:14ORPHAN DRUG ACT 3.11.13
ORPHAN DRUG ACT 3.11.13ORPHAN DRUG ACT 3.11.13
-
1:38How to bring an orphan drug to market - applying for designation
How to bring an orphan drug to market - applying for designationHow to bring an orphan drug to market - applying for designation
12 Hour MBA in Orphan Drugs The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk. In just 12 hours you will: - Gain a comprehensive overview of the orphan drugs industry and market - Look at worldwide orphan drugs legislation - Discover market access procedures for orphan drugs - Understand some of the challenges that patients with rare diseases have to face - Learn about the role of advocacy groups and rare disease networks - Find out how rare disease research is funded in Europe and the US - Discuss the importance of the value proposition For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Orphan-Drugs -
25:43Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13
Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13
Chris Garabedian, Chief Executive Officer of Sarepta Therapeutics, presented at World Orphan Drug Congress USA 2013 on the topic, 'Leveraging a personalized medicine platform: an approach to treat all patient genetic sub-groups in a rare disease.' • Establishing a foundation of evidence • Standardizing the preclinical and clinical approach • The regulatory environment World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease. -
3:01The Annual Cost of Orphan Drugs
The Annual Cost of Orphan DrugsThe Annual Cost of Orphan Drugs
In this exclusive interview with Rare Disease Report, Ms Divino discusses the study’s methods, results, and conclusions. For complete details of the study, click here. https://ash.confex.com/ash/2014/webprogram/Paper68994.html Reference Divino V, Dekoven M, Wang W, et al. Budget impact of orphan drugs in U.S.: A 2007-2013 MIDAS data sales analysis. Presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco. Abstract #736. -
2:1741NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13
41NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13 -
14:07The Orphan Drug Act of 1983
The Orphan Drug Act of 1983The Orphan Drug Act of 1983
A presentation for BTEC 2320, describing the events before and the circumstances surrounding the Orphan Drug Act of 1983, and the Rare Disease Industry. -
31:27FDA orphan designation
FDA orphan designationFDA orphan designation
Speaker: James H. Reese (FDA) First plenary session: orphan designation around the World Worldwide Orphan Medicinal Designation Workshop 10 March 2014
-
Orphan Drugs -- small market/big opportunity / Craig Kephart, President , Centric Health Resources
Why an Orphan market should be approached differently What is done differently in Orphan markets compared to larger markets How to leverage Orphan market dynamics to drive value for your product
published: 03 Feb 2012 -
How to bring an orphan drug to market - why is there legislation for rare diseases?
12 Hour MBA in Orphan Drugs The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk. In just 12 hours you will: - Gain a comprehensive overview of the orphan drugs industry and market - Look at worldwide orphan drugs legislation - Discover market access procedures for orphan drugs - Understand some of the challenges that patients with rare diseases have to face - Learn about the role of advocacy groups and rare disease networks - Find out how rare disease research is funded in Europe and the US - Discuss th...
published: 28 Jan 2013 -
Taking Advantage of the Orphan Drug Act - Webinar
published: 20 May 2015 -
ORPHAN DRUG ACT 3.11.13
published: 12 Mar 2013 -
How to bring an orphan drug to market - applying for designation
12 Hour MBA in Orphan Drugs The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk. In just 12 hours you will: - Gain a comprehensive overview of the orphan drugs industry and market - Look at worldwide orphan drugs legislation - Discover market access procedures for orphan drugs - Understand some of the challenges that patients with rare diseases have to face - Learn about the role of advocacy groups and rare disease networks - Find out how rare disease research is funded in Europe and the US - Discuss th...
published: 28 Jan 2013 -
Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13
Chris Garabedian, Chief Executive Officer of Sarepta Therapeutics, presented at World Orphan Drug Congress USA 2013 on the topic, 'Leveraging a personalized medicine platform: an approach to treat all patient genetic sub-groups in a rare disease.' • Establishing a foundation of evidence • Standardizing the preclinical and clinical approach • The regulatory environment World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
published: 13 May 2013 -
The Annual Cost of Orphan Drugs
In this exclusive interview with Rare Disease Report, Ms Divino discusses the study’s methods, results, and conclusions. For complete details of the study, click here. https://ash.confex.com/ash/2014/webprogram/Paper68994.html Reference Divino V, Dekoven M, Wang W, et al. Budget impact of orphan drugs in U.S.: A 2007-2013 MIDAS data sales analysis. Presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco. Abstract #736.
published: 10 Dec 2014 -
-
The Orphan Drug Act of 1983
A presentation for BTEC 2320, describing the events before and the circumstances surrounding the Orphan Drug Act of 1983, and the Rare Disease Industry.
published: 16 Nov 2011 -
FDA orphan designation
Speaker: James H. Reese (FDA) First plenary session: orphan designation around the World Worldwide Orphan Medicinal Designation Workshop 10 March 2014
published: 03 Apr 2014
Orphan Drugs -- small market/big opportunity / Craig Kephart, President , Centric Health Resources
- Order: Reorder
- Duration: 21:45
- Updated: 03 Feb 2012
- views: 2245
Why an Orphan market should be approached differently
What is done differently in Orphan markets compared to larger markets
How to leverage Orphan marke...
Why an Orphan market should be approached differently
What is done differently in Orphan markets compared to larger markets
How to leverage Orphan market dynamics to drive value for your product
wn.com/Orphan Drugs Small Market Big Opportunity Craig Kephart, President , Centric Health Resources
How to bring an orphan drug to market - why is there legislation for rare diseases?
- Order: Reorder
- Duration: 2:10
- Updated: 28 Jan 2013
- views: 559
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most usefu...
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk.
In just 12 hours you will:
- Gain a comprehensive overview of the orphan drugs industry and market
- Look at worldwide orphan drugs legislation
- Discover market access procedures for orphan drugs
- Understand some of the challenges that patients with rare diseases have to face
- Learn about the role of advocacy groups and rare disease networks
- Find out how rare disease research is funded in Europe and the US
- Discuss the importance of the value proposition
For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Orphan-Drugs
wn.com/How To Bring An Orphan Drug To Market Why Is There Legislation For Rare Diseases
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk.
In just 12 hours you will:
- Gain a comprehensive overview of the orphan drugs industry and market
- Look at worldwide orphan drugs legislation
- Discover market access procedures for orphan drugs
- Understand some of the challenges that patients with rare diseases have to face
- Learn about the role of advocacy groups and rare disease networks
- Find out how rare disease research is funded in Europe and the US
- Discuss the importance of the value proposition
For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Orphan-Drugs
- published: 28 Jan 2013
- views: 559
Taking Advantage of the Orphan Drug Act - Webinar
- Order: Reorder
- Duration: 48:54
- Updated: 20 May 2015
- views: 786
- published: 20 May 2015
- views: 786
ORPHAN DRUG ACT 3.11.13
- Order: Reorder
- Duration: 2:14
- Updated: 12 Mar 2013
- views: 397
- published: 12 Mar 2013
- views: 397
How to bring an orphan drug to market - applying for designation
- Order: Reorder
- Duration: 1:38
- Updated: 28 Jan 2013
- views: 200
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most usefu...
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk.
In just 12 hours you will:
- Gain a comprehensive overview of the orphan drugs industry and market
- Look at worldwide orphan drugs legislation
- Discover market access procedures for orphan drugs
- Understand some of the challenges that patients with rare diseases have to face
- Learn about the role of advocacy groups and rare disease networks
- Find out how rare disease research is funded in Europe and the US
- Discuss the importance of the value proposition
For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Orphan-Drugs
wn.com/How To Bring An Orphan Drug To Market Applying For Designation
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field. Explore real-world lessons they don't teach you on the job, from the comfort of your desk.
In just 12 hours you will:
- Gain a comprehensive overview of the orphan drugs industry and market
- Look at worldwide orphan drugs legislation
- Discover market access procedures for orphan drugs
- Understand some of the challenges that patients with rare diseases have to face
- Learn about the role of advocacy groups and rare disease networks
- Find out how rare disease research is funded in Europe and the US
- Discuss the importance of the value proposition
For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Orphan-Drugs
- published: 28 Jan 2013
- views: 200
Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13
- Order: Reorder
- Duration: 25:43
- Updated: 13 May 2013
- views: 1113
Chris Garabedian, Chief Executive Officer of Sarepta Therapeutics, presented at World Orphan Drug Congress USA 2013 on the topic, 'Leveraging a personalized med...
Chris Garabedian, Chief Executive Officer of Sarepta Therapeutics, presented at World Orphan Drug Congress USA 2013 on the topic, 'Leveraging a personalized medicine platform: an approach to treat all patient genetic sub-groups in a rare disease.'
• Establishing a foundation of evidence
• Standardizing the preclinical and clinical approach
• The regulatory environment
World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development.
For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
wn.com/Chris Garabedian Of Sarepta On Personalized Medicine At World Orphan Drug Congress USA 13
Chris Garabedian, Chief Executive Officer of Sarepta Therapeutics, presented at World Orphan Drug Congress USA 2013 on the topic, 'Leveraging a personalized medicine platform: an approach to treat all patient genetic sub-groups in a rare disease.'
• Establishing a foundation of evidence
• Standardizing the preclinical and clinical approach
• The regulatory environment
World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development.
For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
- published: 13 May 2013
- views: 1113
The Annual Cost of Orphan Drugs
- Order: Reorder
- Duration: 3:01
- Updated: 10 Dec 2014
- views: 186
In this exclusive interview with Rare Disease Report, Ms Divino discusses the study’s methods, results, and conclusions. For complete details of the study, clic...
In this exclusive interview with Rare Disease Report, Ms Divino discusses the study’s methods, results, and conclusions. For complete details of the study, click here. https://ash.confex.com/ash/2014/webprogram/Paper68994.html
Reference
Divino V, Dekoven M, Wang W, et al. Budget impact of orphan drugs in U.S.: A 2007-2013 MIDAS data sales analysis. Presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco. Abstract #736.
wn.com/The Annual Cost Of Orphan Drugs
In this exclusive interview with Rare Disease Report, Ms Divino discusses the study’s methods, results, and conclusions. For complete details of the study, click here. https://ash.confex.com/ash/2014/webprogram/Paper68994.html
Reference
Divino V, Dekoven M, Wang W, et al. Budget impact of orphan drugs in U.S.: A 2007-2013 MIDAS data sales analysis. Presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco. Abstract #736.
- published: 10 Dec 2014
- views: 186
41NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13
- Order: Reorder
- Duration: 2:17
- Updated: 07 May 2013
- views: 196
It's been three decades since legislation gave people with rare diseases more options to live a better life and one man here in Macon is living life to the full...
It's been three decades since legislation gave people with rare diseases more options to live a better life and one man here in Macon is living life to the fullest because of it.
wn.com/41Nbc Wmgt Orphan Drug Act Jameson's Story 5.07.13
The Orphan Drug Act of 1983
- Order: Reorder
- Duration: 14:07
- Updated: 16 Nov 2011
- views: 200
A presentation for BTEC 2320, describing the events before and the circumstances surrounding the Orphan Drug Act of 1983, and the Rare Disease Industry.
A presentation for BTEC 2320, describing the events before and the circumstances surrounding the Orphan Drug Act of 1983, and the Rare Disease Industry.
wn.com/The Orphan Drug Act Of 1983
A presentation for BTEC 2320, describing the events before and the circumstances surrounding the Orphan Drug Act of 1983, and the Rare Disease Industry.
- published: 16 Nov 2011
- views: 200
FDA orphan designation
- Order: Reorder
- Duration: 31:27
- Updated: 03 Apr 2014
- views: 439
Speaker: James H. Reese (FDA)
First plenary session: orphan designation around the World
Worldwide Orphan Medicinal Designation Workshop
10 March 2014
Speaker: James H. Reese (FDA)
First plenary session: orphan designation around the World
Worldwide Orphan Medicinal Designation Workshop
10 March 2014
wn.com/Fda Orphan Designation
Speaker: James H. Reese (FDA)
First plenary session: orphan designation around the World
Worldwide Orphan Medicinal Designation Workshop
10 March 2014
- published: 03 Apr 2014
- views: 439
-
Orphan Products Clinical Trials Grant
Orphan products grants program supports the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA OOPD provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products.
published: 04 Nov 2016 -
US Orphan Drug Market Outlook 2018
“US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to US orphan drug market: US Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework US Orphan Drug Pipeline by Phase, Indication & Originator Marketed Orphan drug List by Indication & Brand Name Key Issue to be Resolved Competitive Landscape
published: 02 Nov 2016 -
Global Orphan Drug Market Outlook 2018
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market: Global & Regional Orphan Drug Market Overview Orphan Drug Designation Criteria Across Key Markets Market Specific Reimbursement Policy & Regulatory Framework Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country Competitive Landscape
published: 02 Nov 2016 -
Global Orphan Drug Market Future Outlook 2020
"Global Orphan Drug Market Future Outlook 2020" report highlights: Global Orphan Drug Market Overview Global Orphan Drug Market Segment Analysis FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs Orphan Drug Designation Criteria & Reimbursement Policy by Region Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase Global Orphan Drugs Clinical Pipeline: 697 Drugs Majority Orphan Drugs in Phase-II Trials: 249 Drugs Marketed Orphan Drugs: 274 Drugs
published: 02 Nov 2016 -
Global Orphan Cancer Drug Market & Clinical Pipeline Insight
“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights: Orphan Cancer Drug Market Outlook Orphan Drug Designation Criteria: US, Europe & Asia Reimbursement Policy: US, Europe & Asia Regulatory Framework: FDA & EMA Guidelines Orphan Cancer Drugs Clinical Pipeline by Phase, Country & Target Indications Orphan Cancer Drug Patent Analysis Orphan Cancer Drug in Development Phase: 235 Majority of Orphan Cancer Drugs in Phase-II: 81 Marketed Orphan Cancer Drugs: 70
published: 02 Nov 2016 -
Europe Orphan Drug Market Outlook 2018
“Europe Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to Europe orphan drug market: Europe Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework Europe Orphan Drug Pipeline by Phase, Indication & Originator Marketed Orphan drug List by Indication & Brand Name Key Issue to be Addressed Competitive Landscape
published: 02 Nov 2016 -
Canadians Fragmented System for Orphan Drugs
Brad Crittendale, president of the Canadian Association of Pompe talks about the current regional systems that are set up to dispense orphan drugs to Canadians and why this fragmented system is one of the reasons why the country needs an Orphan Drug Framework at the national level.
published: 01 Nov 2016 -
Annual Congress on Rare Diseases and Orphan Drugs
Conferenceseries LLC invites all the participants from all over the world to attend ‘Annual Congress on Rare Diseases and Orphan Drugs’ during Oct 26-27, 2016 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. This scientific gathering guarantees that offering the thoughts and ideas will enable and secure you the theme “The voice of rare diseases - research and treatment”. Rare Diseases-2016 is a global platform to discuss and learn about Rare Diseases, rare cancer, morgellons, renal cell carcinoma, malignant glioma, Turner syndrome, Multiple myeloma, Hepatocellular carcinoma, Diabetes in the young, Systemic Amyloidosis, Autoimmune diseases, Disorders of genetic origin, idiopathic disorders, rare genetic diseases, Orphan Drugs, Al...
published: 24 Oct 2016 -
Audiobook: Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases
Get your free audiobook or ebook: http://zaxo.space/mabk/30/en/B00LBXYKVU/book Rare Diseases and Orphan Drugs shows that much of what we now know about common diseases has been achieved by studying rare diseases. It proposes that future advances in the prevention, diagnosis, and treatment of common diseases will come as a consequence of our accelerating progress in the field of rare diseases. Understanding the complex steps in the development of common diseases, such as cancer, cardiovascular disease, and metabolic diseases, has proven a difficult problem. Rare diseases, however, are often caused by aberrations of a single gene. In rare diseases, we may study how specific genetic defects can trigger a series of events that lead to the expression of a particular disease. Often, the disease ...
published: 22 Oct 2016 -
Orphan Drugs: Understanding the Rare Disease Market and its Dynamics Audiobook
Listen to the full audiobook, or read it's ebook version: http://downloadapp.us/mabk/30/en/B00H1YWV3C/book This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the Us and Europe. Before the orphan drug legislation enacted in the Us in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.the journey from application of an orphan drug designation to...
published: 15 Oct 2016
Orphan Products Clinical Trials Grant
- Order: Reorder
- Duration: 3:40
- Updated: 04 Nov 2016
- views: 1
Orphan products grants program supports the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the...
Orphan products grants program supports the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA OOPD provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products.
wn.com/Orphan Products Clinical Trials Grant
Orphan products grants program supports the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA OOPD provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products.
- published: 04 Nov 2016
- views: 1
US Orphan Drug Market Outlook 2018
- Order: Reorder
- Duration: 0:36
- Updated: 02 Nov 2016
- views: 0
“US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to US orphan drug market:
US Or...
“US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to US orphan drug market:
US Orphan Drug Market Overview
Orphan Drug Designation Criteria
Market Specific Reimbursement Policy & Regulatory Framework
US Orphan Drug Pipeline by Phase, Indication & Originator
Marketed Orphan drug List by Indication & Brand Name
Key Issue to be Resolved
Competitive Landscape
wn.com/US Orphan Drug Market Outlook 2018
“US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to US orphan drug market:
US Orphan Drug Market Overview
Orphan Drug Designation Criteria
Market Specific Reimbursement Policy & Regulatory Framework
US Orphan Drug Pipeline by Phase, Indication & Originator
Marketed Orphan drug List by Indication & Brand Name
Key Issue to be Resolved
Competitive Landscape
- published: 02 Nov 2016
- views: 0
Global Orphan Drug Market Outlook 2018
- Order: Reorder
- Duration: 0:36
- Updated: 02 Nov 2016
- views: 0
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:...
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Competitive Landscape
wn.com/Global Orphan Drug Market Outlook 2018
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Competitive Landscape
- published: 02 Nov 2016
- views: 0
Global Orphan Drug Market Future Outlook 2020
- Order: Reorder
- Duration: 0:42
- Updated: 02 Nov 2016
- views: 0
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regu...
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
Orphan Drug Designation Criteria & Reimbursement Policy by Region
Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
Global Orphan Drugs Clinical Pipeline: 697 Drugs
Majority Orphan Drugs in Phase-II Trials: 249 Drugs
Marketed Orphan Drugs: 274 Drugs
wn.com/Global Orphan Drug Market Future Outlook 2020
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
Orphan Drug Designation Criteria & Reimbursement Policy by Region
Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
Global Orphan Drugs Clinical Pipeline: 697 Drugs
Majority Orphan Drugs in Phase-II Trials: 249 Drugs
Marketed Orphan Drugs: 274 Drugs
- published: 02 Nov 2016
- views: 0
Global Orphan Cancer Drug Market & Clinical Pipeline Insight
- Order: Reorder
- Duration: 0:42
- Updated: 02 Nov 2016
- views: 0
“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights:
Orphan Cancer Drug Market Outlook
Orphan Drug Designation Criteria: US, Euro...
“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights:
Orphan Cancer Drug Market Outlook
Orphan Drug Designation Criteria: US, Europe & Asia
Reimbursement Policy: US, Europe & Asia
Regulatory Framework: FDA & EMA Guidelines
Orphan Cancer Drugs Clinical Pipeline by Phase, Country & Target Indications
Orphan Cancer Drug Patent Analysis
Orphan Cancer Drug in Development Phase: 235
Majority of Orphan Cancer Drugs in Phase-II: 81
Marketed Orphan Cancer Drugs: 70
wn.com/Global Orphan Cancer Drug Market Clinical Pipeline Insight
“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights:
Orphan Cancer Drug Market Outlook
Orphan Drug Designation Criteria: US, Europe & Asia
Reimbursement Policy: US, Europe & Asia
Regulatory Framework: FDA & EMA Guidelines
Orphan Cancer Drugs Clinical Pipeline by Phase, Country & Target Indications
Orphan Cancer Drug Patent Analysis
Orphan Cancer Drug in Development Phase: 235
Majority of Orphan Cancer Drugs in Phase-II: 81
Marketed Orphan Cancer Drugs: 70
- published: 02 Nov 2016
- views: 0
Europe Orphan Drug Market Outlook 2018
- Order: Reorder
- Duration: 0:36
- Updated: 02 Nov 2016
- views: 0
“Europe Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to Europe orphan drug market:...
“Europe Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to Europe orphan drug market:
Europe Orphan Drug Market Overview
Orphan Drug Designation Criteria
Market Specific Reimbursement Policy & Regulatory Framework
Europe Orphan Drug Pipeline by Phase, Indication & Originator
Marketed Orphan drug List by Indication & Brand Name
Key Issue to be Addressed
Competitive Landscape
wn.com/Europe Orphan Drug Market Outlook 2018
“Europe Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to Europe orphan drug market:
Europe Orphan Drug Market Overview
Orphan Drug Designation Criteria
Market Specific Reimbursement Policy & Regulatory Framework
Europe Orphan Drug Pipeline by Phase, Indication & Originator
Marketed Orphan drug List by Indication & Brand Name
Key Issue to be Addressed
Competitive Landscape
- published: 02 Nov 2016
- views: 0
Canadians Fragmented System for Orphan Drugs
- Order: Reorder
- Duration: 1:32
- Updated: 01 Nov 2016
- views: 19
Brad Crittendale, president of the Canadian Association of Pompe talks about the current regional systems that are set up to dispense orphan drugs to Canadians ...
Brad Crittendale, president of the Canadian Association of Pompe talks about the current regional systems that are set up to dispense orphan drugs to Canadians and why this fragmented system is one of the reasons why the country needs an Orphan Drug Framework at the national level.
wn.com/Canadians Fragmented System For Orphan Drugs
Brad Crittendale, president of the Canadian Association of Pompe talks about the current regional systems that are set up to dispense orphan drugs to Canadians and why this fragmented system is one of the reasons why the country needs an Orphan Drug Framework at the national level.
- published: 01 Nov 2016
- views: 19
Annual Congress on Rare Diseases and Orphan Drugs
- Order: Reorder
- Duration: 2:20
- Updated: 24 Oct 2016
- views: 10
Conferenceseries LLC invites all the participants from all over the world to attend ‘Annual Congress on Rare Diseases and Orphan Drugs’ during Oct 26-27, 2016 i...
Conferenceseries LLC invites all the participants from all over the world to attend ‘Annual Congress on Rare Diseases and Orphan Drugs’ during Oct 26-27, 2016 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. This scientific gathering guarantees that offering the thoughts and ideas will enable and secure you the theme “The voice of rare diseases - research and treatment”. Rare Diseases-2016 is a global platform to discuss and learn about Rare Diseases, rare cancer, morgellons, renal cell carcinoma, malignant glioma, Turner syndrome, Multiple myeloma, Hepatocellular carcinoma, Diabetes in the young, Systemic Amyloidosis, Autoimmune diseases, Disorders of genetic origin, idiopathic disorders, rare genetic diseases, Orphan Drugs, Alzheimer’s Disease and many more.
wn.com/Annual Congress On Rare Diseases And Orphan Drugs
Conferenceseries LLC invites all the participants from all over the world to attend ‘Annual Congress on Rare Diseases and Orphan Drugs’ during Oct 26-27, 2016 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. This scientific gathering guarantees that offering the thoughts and ideas will enable and secure you the theme “The voice of rare diseases - research and treatment”. Rare Diseases-2016 is a global platform to discuss and learn about Rare Diseases, rare cancer, morgellons, renal cell carcinoma, malignant glioma, Turner syndrome, Multiple myeloma, Hepatocellular carcinoma, Diabetes in the young, Systemic Amyloidosis, Autoimmune diseases, Disorders of genetic origin, idiopathic disorders, rare genetic diseases, Orphan Drugs, Alzheimer’s Disease and many more.
- published: 24 Oct 2016
- views: 10
Audiobook: Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases
- Order: Reorder
- Duration: 2:27
- Updated: 22 Oct 2016
- views: 0
Get your free audiobook or ebook: http://zaxo.space/mabk/30/en/B00LBXYKVU/book
Rare Diseases and Orphan Drugs shows that much of what we now know about common d...
Get your free audiobook or ebook: http://zaxo.space/mabk/30/en/B00LBXYKVU/book
Rare Diseases and Orphan Drugs shows that much of what we now know about common diseases has been achieved by studying rare diseases. It proposes that future advances in the prevention, diagnosis, and treatment of common diseases will come as a consequence of our accelerating progress in the field of rare diseases. Understanding the complex steps in the development of common diseases, such as cancer, cardiovascular disease, and metabolic diseases, has proven a difficult problem. Rare diseases, however, are often caused by aberrations of a single gene. In rare diseases, we may study how specific genetic defects can trigger a series of events that lead to the expression of a particular disease. Often, the disease process manifested in a certain rare disease is strikingly similar to the disease process observed in a common disease. This work ties the lessons learned about rare diseases to our understanding of common ones. Chapters covering the number of common diseases are minimized, while rare diseases are introduced as single diseases or as members of diseases classes. After reading this book, readers will appreciate how further research into the rare diseases may lead to new methods for preventing, diagnosing, and treating all diseases, rare or common.makes rare diseases relevant to clinicians and researchers by tying lessons learned about the rare diseases to our understanding of the common diseasesstresses basic pathologic mechanisms that account for human disease (e.g., disorders of cell development, replication, maintenance, function and structure), that can be understood without prior training in pathologydiscusses advanced concepts in molecular biology and genetics in a simple, functional context appropriate for medical trainees and new researchersoffers insights into how further research into rare diseases may lead to new methods for preventing, diagnosing, and treating all diseases.
wn.com/Audiobook Rare Diseases And Orphan Drugs Keys To Understanding And Treating The Common Diseases
Get your free audiobook or ebook: http://zaxo.space/mabk/30/en/B00LBXYKVU/book
Rare Diseases and Orphan Drugs shows that much of what we now know about common diseases has been achieved by studying rare diseases. It proposes that future advances in the prevention, diagnosis, and treatment of common diseases will come as a consequence of our accelerating progress in the field of rare diseases. Understanding the complex steps in the development of common diseases, such as cancer, cardiovascular disease, and metabolic diseases, has proven a difficult problem. Rare diseases, however, are often caused by aberrations of a single gene. In rare diseases, we may study how specific genetic defects can trigger a series of events that lead to the expression of a particular disease. Often, the disease process manifested in a certain rare disease is strikingly similar to the disease process observed in a common disease. This work ties the lessons learned about rare diseases to our understanding of common ones. Chapters covering the number of common diseases are minimized, while rare diseases are introduced as single diseases or as members of diseases classes. After reading this book, readers will appreciate how further research into the rare diseases may lead to new methods for preventing, diagnosing, and treating all diseases, rare or common.makes rare diseases relevant to clinicians and researchers by tying lessons learned about the rare diseases to our understanding of the common diseasesstresses basic pathologic mechanisms that account for human disease (e.g., disorders of cell development, replication, maintenance, function and structure), that can be understood without prior training in pathologydiscusses advanced concepts in molecular biology and genetics in a simple, functional context appropriate for medical trainees and new researchersoffers insights into how further research into rare diseases may lead to new methods for preventing, diagnosing, and treating all diseases.
- published: 22 Oct 2016
- views: 0
Orphan Drugs: Understanding the Rare Disease Market and its Dynamics Audiobook
- Order: Reorder
- Duration: 2:29
- Updated: 15 Oct 2016
- views: 1
Listen to the full audiobook, or read it's ebook version: http://downloadapp.us/mabk/30/en/B00H1YWV3C/book
This authoritative and comprehensive book makes the r...
Listen to the full audiobook, or read it's ebook version: http://downloadapp.us/mabk/30/en/B00H1YWV3C/book
This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the Us and Europe. Before the orphan drug legislation enacted in the Us in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.the journey from application of an orphan drug designation to a reimbursed marketapproved drug is long and many obstacles occur during the journey.after reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.the book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs.a comprehensive overview of strategy, key activities and considerations of how to bring an orphan drug from concept to the market and make it available to patientsa source of updated information, news and trends for those who are already active in this fast-evolving fieldcovers the global definitions and the criteria for getting an orphan drug designation in, for example, the Us and Europe
wn.com/Orphan Drugs Understanding The Rare Disease Market And Its Dynamics Audiobook
Listen to the full audiobook, or read it's ebook version: http://downloadapp.us/mabk/30/en/B00H1YWV3C/book
This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the Us and Europe. Before the orphan drug legislation enacted in the Us in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.the journey from application of an orphan drug designation to a reimbursed marketapproved drug is long and many obstacles occur during the journey.after reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.the book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs.a comprehensive overview of strategy, key activities and considerations of how to bring an orphan drug from concept to the market and make it available to patientsa source of updated information, news and trends for those who are already active in this fast-evolving fieldcovers the global definitions and the criteria for getting an orphan drug designation in, for example, the Us and Europe
- published: 15 Oct 2016
- views: 1
-
Martine Zimmerman of Alexion on Europe's regulatory process at World Orphan Drug Congress USA 2013
Martine Zimmermann, Executive Director Global Regulatory Affairs at Alexion Pharmaceuticals, presented at World Orphan Drug Congress USA 2013 on the topic, 'Where industry stumbles in Europe's orphan drug regulatory process.' World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
published: 15 May 2013 -
Orphan Drugs: Making Rare Disease Rarer
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013 The signing of FDASIA by President Obama in July reinforces the country's commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug. Some companies have even taken a step beyond and focused primarily on ultra rare disease, potentially providing an even more compelling opportunity. This panel will provide an in-depth analysis of the thriving market opportunity that is rare disease by featuring industry, clinical and regulatory experts specializing in this exciting...
published: 27 Feb 2013 -
Early access to orphan drugs – the rationale, challenges and options available
Early access to orphan drugs – the rationale, challenges and options available • Why consider early access? • What are the challenges for early access? • Introduction to the mechanisms, regulatory environment and options for early access. • Current trends in early access • Insight into the potential benefits and risks of early access Mark Corbett, Senior Vice President, Global Access Programs, Clinigen Pharma World Orphan Drug Congress USA 2014
published: 22 Aug 2014 -
Freda Lewis-Hall, MD, Gives Keynote Address at World Orphan Drug Congress USA
On April 10, 2013, Freda Lewis-Hall, MD, Chief Medical Officer of Pfizer, Inc delivered the keynote speech at Terrappin's World Orphan Drug Congress USA 2013 in Washington, D.C. To learn about Pfizer's commitment to rare diseases, go to http://www.pfizer.com/partnering/areas_of_interest/rare_diseases.jsp
published: 18 Jul 2013 -
Myths and realities of the Canadian orphan drug market
MYTHS AND REALITIES OF THE CANADIAN ORPHAN DRUG MARKET, presented by Éric Gervais at the World Orphan Drug Congress Europe, Geneva, November 2013
published: 27 Jan 2014 -
John Maddox of Infusion Pharma Consulting on pricing at World Orphan Drug Congress USA 2013
John Maddox, Managing Director of Infusion Pharma Consulting, presented at World Orphan Drug Congress USA 2013 on the topic, 'The impact of payers financial reality in shifting the orphan drugs pricing environment.' • What happens if the pricing latitude for orphan drugs is discontinued? • How difficult it is to get pricing in a potential low value market? • Competitiveness in the orphan drug space to benefit payers. What are payers' ability to pay? World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare dise...
published: 14 May 2013
Martine Zimmerman of Alexion on Europe's regulatory process at World Orphan Drug Congress USA 2013
- Order: Reorder
- Duration: 29:43
- Updated: 15 May 2013
- views: 1279
Martine Zimmermann, Executive Director Global Regulatory Affairs at Alexion Pharmaceuticals, presented at World Orphan Drug Congress USA 2013 on the topic, 'Whe...
Martine Zimmermann, Executive Director Global Regulatory Affairs at Alexion Pharmaceuticals, presented at World Orphan Drug Congress USA 2013 on the topic, 'Where industry stumbles in Europe's orphan drug regulatory process.'
World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development.
For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
wn.com/Martine Zimmerman Of Alexion On Europe's Regulatory Process At World Orphan Drug Congress USA 2013
Martine Zimmermann, Executive Director Global Regulatory Affairs at Alexion Pharmaceuticals, presented at World Orphan Drug Congress USA 2013 on the topic, 'Where industry stumbles in Europe's orphan drug regulatory process.'
World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development.
For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
- published: 15 May 2013
- views: 1279
Orphan Drugs: Making Rare Disease Rarer
- Order: Reorder
- Duration: 56:56
- Updated: 27 Feb 2013
- views: 1138
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013
The signing of FDASIA by President Obama in ...
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013
The signing of FDASIA by President Obama in July reinforces the country's commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug. Some companies have even taken a step beyond and focused primarily on ultra rare disease, potentially providing an even more compelling opportunity. This panel will provide an in-depth analysis of the thriving market opportunity that is rare disease by featuring industry, clinical and regulatory experts specializing in this exciting field.
Moderator:
Ritu S. Baral, Principal, Sr. Analyst -- Biotechnology Equity Research, Canaccord Genuity
Panelists:
Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals
John F. Crowley, Chairman & CEO, Amicus Therapeutics
Pamela Gavin, Senior Vice President, National Organization for Rare Disorders (NORD)
Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa
Alvin V. Shih, MD, Chief Operating Officer, Pfizer Rare Disease Research Unit
wn.com/Orphan Drugs Making Rare Disease Rarer
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013
The signing of FDASIA by President Obama in July reinforces the country's commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug. Some companies have even taken a step beyond and focused primarily on ultra rare disease, potentially providing an even more compelling opportunity. This panel will provide an in-depth analysis of the thriving market opportunity that is rare disease by featuring industry, clinical and regulatory experts specializing in this exciting field.
Moderator:
Ritu S. Baral, Principal, Sr. Analyst -- Biotechnology Equity Research, Canaccord Genuity
Panelists:
Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals
John F. Crowley, Chairman & CEO, Amicus Therapeutics
Pamela Gavin, Senior Vice President, National Organization for Rare Disorders (NORD)
Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa
Alvin V. Shih, MD, Chief Operating Officer, Pfizer Rare Disease Research Unit
- published: 27 Feb 2013
- views: 1138
Early access to orphan drugs – the rationale, challenges and options available
- Order: Reorder
- Duration: 20:38
- Updated: 22 Aug 2014
- views: 188
Early access to orphan drugs – the rationale, challenges and options available
• Why consider early access?
• What are the challenges for early access?
• Introd...
Early access to orphan drugs – the rationale, challenges and options available
• Why consider early access?
• What are the challenges for early access?
• Introduction to the mechanisms, regulatory environment and options for early access.
• Current trends in early access
• Insight into the potential benefits and risks of early access
Mark Corbett, Senior Vice President, Global Access Programs, Clinigen Pharma
World Orphan Drug Congress USA 2014
wn.com/Early Access To Orphan Drugs – The Rationale, Challenges And Options Available
Early access to orphan drugs – the rationale, challenges and options available
• Why consider early access?
• What are the challenges for early access?
• Introduction to the mechanisms, regulatory environment and options for early access.
• Current trends in early access
• Insight into the potential benefits and risks of early access
Mark Corbett, Senior Vice President, Global Access Programs, Clinigen Pharma
World Orphan Drug Congress USA 2014
- published: 22 Aug 2014
- views: 188
Freda Lewis-Hall, MD, Gives Keynote Address at World Orphan Drug Congress USA
- Order: Reorder
- Duration: 28:05
- Updated: 18 Jul 2013
- views: 1241
On April 10, 2013, Freda Lewis-Hall, MD, Chief Medical Officer of Pfizer, Inc delivered the keynote speech at Terrappin's World Orphan Drug Congress USA 2013 in...
On April 10, 2013, Freda Lewis-Hall, MD, Chief Medical Officer of Pfizer, Inc delivered the keynote speech at Terrappin's World Orphan Drug Congress USA 2013 in Washington, D.C.
To learn about Pfizer's commitment to rare diseases, go to http://www.pfizer.com/partnering/areas_of_interest/rare_diseases.jsp
wn.com/Freda Lewis Hall, Md, Gives Keynote Address At World Orphan Drug Congress USA
On April 10, 2013, Freda Lewis-Hall, MD, Chief Medical Officer of Pfizer, Inc delivered the keynote speech at Terrappin's World Orphan Drug Congress USA 2013 in Washington, D.C.
To learn about Pfizer's commitment to rare diseases, go to http://www.pfizer.com/partnering/areas_of_interest/rare_diseases.jsp
- published: 18 Jul 2013
- views: 1241
Myths and realities of the Canadian orphan drug market
- Order: Reorder
- Duration: 22:20
- Updated: 27 Jan 2014
- views: 194
MYTHS AND REALITIES OF THE CANADIAN ORPHAN DRUG MARKET, presented by Éric Gervais at the World Orphan Drug Congress Europe, Geneva, November 2013
MYTHS AND REALITIES OF THE CANADIAN ORPHAN DRUG MARKET, presented by Éric Gervais at the World Orphan Drug Congress Europe, Geneva, November 2013
wn.com/Myths And Realities Of The Canadian Orphan Drug Market
MYTHS AND REALITIES OF THE CANADIAN ORPHAN DRUG MARKET, presented by Éric Gervais at the World Orphan Drug Congress Europe, Geneva, November 2013
- published: 27 Jan 2014
- views: 194
John Maddox of Infusion Pharma Consulting on pricing at World Orphan Drug Congress USA 2013
- Order: Reorder
- Duration: 22:12
- Updated: 14 May 2013
- views: 323
John Maddox, Managing Director of Infusion Pharma Consulting, presented at World Orphan Drug Congress USA 2013 on the topic, 'The impact of payers financial rea...
John Maddox, Managing Director of Infusion Pharma Consulting, presented at World Orphan Drug Congress USA 2013 on the topic, 'The impact of payers financial reality in shifting the orphan drugs pricing environment.'
• What happens if the pricing latitude for orphan drugs is discontinued?
• How difficult it is to get pricing in a potential low value market?
• Competitiveness in the orphan drug space to benefit payers. What are payers' ability to pay?
World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development.
For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
wn.com/John Maddox Of Infusion Pharma Consulting On Pricing At World Orphan Drug Congress USA 2013
John Maddox, Managing Director of Infusion Pharma Consulting, presented at World Orphan Drug Congress USA 2013 on the topic, 'The impact of payers financial reality in shifting the orphan drugs pricing environment.'
• What happens if the pricing latitude for orphan drugs is discontinued?
• How difficult it is to get pricing in a potential low value market?
• Competitiveness in the orphan drug space to benefit payers. What are payers' ability to pay?
World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development.
For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.
- published: 14 May 2013
- views: 323
back
- Playlist
- Chat
back
- Playlist
- Chat
21:45
Orphan Drugs -- small market/big opportunity / Craig Kephart, President , Centric Health Resources
Why an Orphan market should be approached differently
What is done differently in Orph...
published: 03 Feb 2012
Orphan Drugs -- small market/big opportunity / Craig Kephart, President , Centric Health Resources
Orphan Drugs -- small market/big opportunity / Craig Kephart, President , Centric Health Resources
- Report rights infringement
- published: 03 Feb 2012
- views: 2245
2:10
How to bring an orphan drug to market - why is there legislation for rare diseases?
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level onli...
published: 28 Jan 2013
How to bring an orphan drug to market - why is there legislation for rare diseases?
How to bring an orphan drug to market - why is there legislation for rare diseases?
- Report rights infringement
- published: 28 Jan 2013
- views: 559
48:54
Taking Advantage of the Orphan Drug Act - Webinar
published: 20 May 2015
Taking Advantage of the Orphan Drug Act - Webinar
Taking Advantage of the Orphan Drug Act - Webinar
- Report rights infringement
- published: 20 May 2015
- views: 786
2:14
ORPHAN DRUG ACT 3.11.13
published: 12 Mar 2013
ORPHAN DRUG ACT 3.11.13
ORPHAN DRUG ACT 3.11.13
- Report rights infringement
- published: 12 Mar 2013
- views: 397
1:38
How to bring an orphan drug to market - applying for designation
12 Hour MBA in Orphan Drugs
The 12 Hour MBA in Orphan Drugs is an introductory-level onli...
published: 28 Jan 2013
How to bring an orphan drug to market - applying for designation
How to bring an orphan drug to market - applying for designation
- Report rights infringement
- published: 28 Jan 2013
- views: 200
25:43
Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13
Chris Garabedian, Chief Executive Officer of Sarepta Therapeutics, presented at World Orph...
published: 13 May 2013
Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13
Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13
- Report rights infringement
- published: 13 May 2013
- views: 1113
3:01
The Annual Cost of Orphan Drugs
In this exclusive interview with Rare Disease Report, Ms Divino discusses the study’s meth...
published: 10 Dec 2014
The Annual Cost of Orphan Drugs
The Annual Cost of Orphan Drugs
- Report rights infringement
- published: 10 Dec 2014
- views: 186
2:17
41NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13
It's been three decades since legislation gave people with rare diseases more options to l...
published: 07 May 2013
41NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13
41NBC/WMGT - Orphan Drug Act: Jameson's Story - 5.07.13
- Report rights infringement
- published: 07 May 2013
- views: 196
14:07
The Orphan Drug Act of 1983
A presentation for BTEC 2320, describing the events before and the circumstances surroundi...
published: 16 Nov 2011
The Orphan Drug Act of 1983
The Orphan Drug Act of 1983
- Report rights infringement
- published: 16 Nov 2011
- views: 200
31:27
FDA orphan designation
Speaker: James H. Reese (FDA)
First plenary session: orphan designation around the World
...
published: 03 Apr 2014
FDA orphan designation
FDA orphan designation
- Report rights infringement
- published: 03 Apr 2014
- views: 439
back
- Playlist
- Chat
3:40
Orphan Products Clinical Trials Grant
Orphan products grants program supports the clinical development of products for use in ra...
published: 04 Nov 2016
Orphan Products Clinical Trials Grant
Orphan Products Clinical Trials Grant
- Report rights infringement
- published: 04 Nov 2016
- views: 1
0:36
US Orphan Drug Market Outlook 2018
“US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insig...
published: 02 Nov 2016
US Orphan Drug Market Outlook 2018
US Orphan Drug Market Outlook 2018
- Report rights infringement
- published: 02 Nov 2016
- views: 0
0:36
Global Orphan Drug Market Outlook 2018
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive i...
published: 02 Nov 2016
Global Orphan Drug Market Outlook 2018
Global Orphan Drug Market Outlook 2018
- Report rights infringement
- published: 02 Nov 2016
- views: 0
0:42
Global Orphan Drug Market Future Outlook 2020
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Mar...
published: 02 Nov 2016
Global Orphan Drug Market Future Outlook 2020
Global Orphan Drug Market Future Outlook 2020
- Report rights infringement
- published: 02 Nov 2016
- views: 0
0:42
Global Orphan Cancer Drug Market & Clinical Pipeline Insight
“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights:
Orphan...
published: 02 Nov 2016
Global Orphan Cancer Drug Market & Clinical Pipeline Insight
Global Orphan Cancer Drug Market & Clinical Pipeline Insight
- Report rights infringement
- published: 02 Nov 2016
- views: 0
0:36
Europe Orphan Drug Market Outlook 2018
“Europe Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive i...
published: 02 Nov 2016
Europe Orphan Drug Market Outlook 2018
Europe Orphan Drug Market Outlook 2018
- Report rights infringement
- published: 02 Nov 2016
- views: 0
1:32
Canadians Fragmented System for Orphan Drugs
Brad Crittendale, president of the Canadian Association of Pompe talks about the current r...
published: 01 Nov 2016
Canadians Fragmented System for Orphan Drugs
Canadians Fragmented System for Orphan Drugs
- Report rights infringement
- published: 01 Nov 2016
- views: 19
2:20
Annual Congress on Rare Diseases and Orphan Drugs
Conferenceseries LLC invites all the participants from all over the world to attend ‘Annua...
published: 24 Oct 2016
Annual Congress on Rare Diseases and Orphan Drugs
Annual Congress on Rare Diseases and Orphan Drugs
- Report rights infringement
- published: 24 Oct 2016
- views: 10
2:27
Audiobook: Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases
Get your free audiobook or ebook: http://zaxo.space/mabk/30/en/B00LBXYKVU/book
Rare Diseas...
published: 22 Oct 2016
Audiobook: Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases
Audiobook: Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases
- Report rights infringement
- published: 22 Oct 2016
- views: 0
2:29
Orphan Drugs: Understanding the Rare Disease Market and its Dynamics Audiobook
Listen to the full audiobook, or read it's ebook version: http://downloadapp.us/mabk/30/en...
published: 15 Oct 2016
Orphan Drugs: Understanding the Rare Disease Market and its Dynamics Audiobook
Orphan Drugs: Understanding the Rare Disease Market and its Dynamics Audiobook
- Report rights infringement
- published: 15 Oct 2016
- views: 1
back
- Playlist
- Chat
29:43
Martine Zimmerman of Alexion on Europe's regulatory process at World Orphan Drug Congress USA 2013
Martine Zimmermann, Executive Director Global Regulatory Affairs at Alexion Pharmaceutical...
published: 15 May 2013
Martine Zimmerman of Alexion on Europe's regulatory process at World Orphan Drug Congress USA 2013
Martine Zimmerman of Alexion on Europe's regulatory process at World Orphan Drug Congress USA 2013
- Report rights infringement
- published: 15 May 2013
- views: 1279
56:56
Orphan Drugs: Making Rare Disease Rarer
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New Yor...
published: 27 Feb 2013
Orphan Drugs: Making Rare Disease Rarer
Orphan Drugs: Making Rare Disease Rarer
- Report rights infringement
- published: 27 Feb 2013
- views: 1138
20:38
Early access to orphan drugs – the rationale, challenges and options available
Early access to orphan drugs – the rationale, challenges and options available
• Why consi...
published: 22 Aug 2014
Early access to orphan drugs – the rationale, challenges and options available
Early access to orphan drugs – the rationale, challenges and options available
- Report rights infringement
- published: 22 Aug 2014
- views: 188
28:05
Freda Lewis-Hall, MD, Gives Keynote Address at World Orphan Drug Congress USA
On April 10, 2013, Freda Lewis-Hall, MD, Chief Medical Officer of Pfizer, Inc delivered th...
published: 18 Jul 2013
Freda Lewis-Hall, MD, Gives Keynote Address at World Orphan Drug Congress USA
Freda Lewis-Hall, MD, Gives Keynote Address at World Orphan Drug Congress USA
- Report rights infringement
- published: 18 Jul 2013
- views: 1241
22:20
Myths and realities of the Canadian orphan drug market
MYTHS AND REALITIES OF THE CANADIAN ORPHAN DRUG MARKET, presented by Éric Gervais at the W...
published: 27 Jan 2014
Myths and realities of the Canadian orphan drug market
Myths and realities of the Canadian orphan drug market
- Report rights infringement
- published: 27 Jan 2014
- views: 194
22:12
John Maddox of Infusion Pharma Consulting on pricing at World Orphan Drug Congress USA 2013
John Maddox, Managing Director of Infusion Pharma Consulting, presented at World Orphan Dr...
published: 14 May 2013
John Maddox of Infusion Pharma Consulting on pricing at World Orphan Drug Congress USA 2013
John Maddox of Infusion Pharma Consulting on pricing at World Orphan Drug Congress USA 2013
- Report rights infringement
- published: 14 May 2013
- views: 323
Martine Zimmerman of Alexion on Europe's regulator...
Orphan Drugs: Making Rare Disease Rarer...
Early access to orphan drugs – the rationale, chal...
Freda Lewis-Hall, MD, Gives Keynote Address at Wor...
Myths and realities of the Canadian orphan drug ma...
John Maddox of Infusion Pharma Consulting on prici...
back
Tsunami hits New Zealand after massive quake
Edit Yahoo Daily News 13 Nov 2016
By Charlotte Greenfield. WELLINGTON (Reuters) - An earthquake with a magnitude of 7.8 struck central New Zealand just after midnight, the U.S. Geological Survey said, causing widespread damage and generating a tsunami. New Zealand's Ministry of Civil Defence and Emergency Management warned of the risk of destructive waves along the country's entire east coast and urged residents in low-lying areas to evacuate and seek higher ground ... ....
back
What Donald Trump taught us about ourselves
Edit CNN 13 Nov 2016
(CNN)Welcome to Donald Trump's America. In the aftermath of his improbable victory and on the cusp of a presidency fueled by a movement that could signal a generational realignment in American politics, the country emerges deeply divided -- and with so many feeling that there are further reckonings to come ... For all his idiosyncrasies, Trump had one thing very much in common with other outsized cultural figures ... 1. The U.S ... Read More ... 2 ... 3 ... ....
back
Clinton Was Reportedly Inconsolable After Election Loss
Edit Opposing Views 12 Nov 2016
Hillary Clinton was reportedly inconsolable after the announcement that Donald Trump had beat her in the presidential election. Clinton “couldn’t stop crying,” conservative author Ed Klein said a source told him November 9 on Newsmax TV’s “The Steve Malzberg Show.”. "About 6.30 [the] morning [of November 9] she called an old friend," he said. "She was crying, inconsolably.” ... Trump is unfit to serve ... ....
back
'Impossible' space engine may actually work: NASA
Edit The Times of India 13 Nov 2016
HOUSTON. A controversial and puzzling engine design that could potentially make space travel much cheaper and faster may actually work, a new NASA study suggests. The experimental propulsion system known as the EmDrive, which seems to violate the laws of physics, generated small amounts of thrust in a lab test, researchers said ... Click here to download it for your device....
Momentum to regulate drug prices uncertain after Prop 61 defeat, Republican victories
Edit LA Daily News 14 Nov 2016
Republican control of the White House and Congress erodes the possibility of federal action to control the price of prescription drugs, health policy experts say. Instead, policymaking to address the spiraling drug costs likely will be done on the state level. Yet the Election Day defeat of a California ballot measure to rein in drug prices may make local lawmakers less inclined to pursue that model of tamping down on drug prices, too....
Underprivileged get a special treat
Edit The Times of India 14 Nov 2016
INDORE ... At the Navdeep Child Welfare Centre, where orphans from 4- day-old to 9-year-old are kept, donors have committed to come to distribute chocolates, new clothes, gifts, toys and teddy bears. The orphanage authorities have made plans to decorate the nursery to make children feel special on Children's Day ... We decorate rooms and distribute sweets and clothes to the elder ones ... RELATED....
Drug manufacturers see new opportunities in U.S.
Edit The Hindu 14 Nov 2016
America has remained the largest market for Indian drug manufacturers as drugs made there are very expensive ... Before bifurcation itself, Visakhapatnam emerged a major pharma hub after Hyderabad in the undivided Andhra Pradesh due to heavy concentration of bulk drug units all over North Andhra region ... Almost 60 to 70 per cent drugs mostly for treatment of life threatening diseases are exported to the United States....
Strengthening Cooperation in the Pharmaceutical Field, the Embassy of the Republic of Indonesia in Kyiv Facilitates the Sig (Ministry of Foreign Affairs of the Republic of Indonesia)
Edit Public Technologies 14 Nov 2016
On November 3-5, 2016, 9 (nine) delegations from the National Agency of Drug and Food Control (NA-DFC) of the Republic of Indonesia together with representatives from the private sector visited Kyiv, Ukraine ... Roman Ilyk, the Acting Head of the State Service of Ukraine on Medicines and Drugs Control (SSUMDC), Ms ... Indonesia hopes that the export of palm oil and drug products can increase....
Heart risks of popular pain relievers still unclear
Edit The Oklahoman 14 Nov 2016
The three drugs studied are part of a class of painkillers called non-steroidal anti-inflammatory drugs, or NSAIDs. They are among the most commonly used drugs in the world, including more than 100 million U.S ... Some are available over-the-counter at low doses while higher-dose drugs require a prescription ... “Less drug exposure means you’re going to have fewer side effects,” FitzGerald said....
3 arthritis pain drugs prove equally safe for the heart
Edit Richmond Times Dispatch 14 Nov 2016
The government required Pfizer, Celebrex's maker, to do this new safety study after the popular arthritis drug Vioxx was withdrawn ... The drugs proved similar ......
If you're 40, older, you should consider taking cholesterol drugs, new guidelines say
Edit The Dallas Morning News 14 Nov 2016
Preventive Services Task Force on Sunday issued new guidance for the use of cholesterol-busting statin drugs ... Should you take a cholesterol-lowering drug? ... In contrast, the ACC/AHA recommends that people with a 7.5 percent or greater risk take the drugs ... They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are "weak," and that the reports of adverse events are incomplete....
$3 million to expand WA Police meth teams (State Government of Western Australia)
Edit Public Technologies 14 Nov 2016
(Source. State Government of Western Australia). 34 extra officers to be recruited to dedicated meth teams. Eight additional vehicles will be purchased ... 'The officers and vehicles will also help enforce the Government's new drug transit route legislation, which targets vehicles travelling through known drug routes as well as courier and freight facilities which are unwittingly being used by drug traffickers.' ... Fact File ... (noodl. 36288337) ....
Reducing Disadvantage Where It Is Needed Most (Premier of Victoria)
Edit Public Technologies 14 Nov 2016
(Source. Premier of Victoria) ... The focus of the SIBs will be to reduce harmful alcohol and other drug use, and assist young people leaving out of home care ... Quotes attributable to Treasurer Tim Pallas. 'As a modern Labor Government that was elected to put people first, we are open to new ideas that can reduce social disadvantage for young people - reducing drug and alcohol use, and assisting those young people leaving out of home care.'....
In '60 Mniutes' interview, Donald Trump says he plans to immediately deport 2 to 3 ...
Edit Omaha World-Herald 14 Nov 2016
"What we are going to do is get the people that are criminal and have criminal records, gang members, drug dealers, where a lot of these people, probably 2 million, it could be even 3 million, we are getting them… ... ....
Drug smugglers lose final death sentence appeal in Indonesia
Edit Topix 14 Nov 2016
The Supreme Court of Indonesia on Friday upheld the death sentence against three Taiwanese men who were convicted last year of smuggling drugs into the country. In its ruling, the court said the crime committed by the three defendants would cause great harm to Indonesians, particularly young people ... ....
Plea to fix minimum price
Edit The Hindu 14 Nov 2016
... at different localities to prevent exploitation by medicine ‘mafia’ and a clampdown on narcotic drugs....
Canadian children now take far more mood-altering drugs, prescription count shows
Edit Canada Dot Com 14 Nov 2016- 1
- 2
- 3
- 4
- 5
- Next page »
